These studies suggest that small-molecule ligands of sortilin can be designed not only to inhibit the function of sortilin but also to enhance its activity and could be used as a therapeutic for diseases in which sortilin activity is beneficial, as in some types of cancers. Here, SORT1 is linked to cancer.